Use este identificador para citar ou linkar para este item: http://higia.imip.org.br/handle/123456789/769
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorMichalowski, Mariana Bohns-
dc.contributor.authorCecconello, Daiane Keller-
dc.contributor.authorLins, Mecneide Mendes-
dc.contributor.authorCarvalho, Maria do Perpétuo Socorro Sampaio-
dc.contributor.authorSilva, Klerize Anecely de Souza-
dc.contributor.authorCristofani, Lilian-
dc.contributor.authorBonilha, Thais Alcantra-
dc.contributor.authorBaglioli, Bianca Faustini-
dc.contributor.authorPianovski, Mara Albonei Dudeque-
dc.contributor.authorKuczynski, Ana Paula-
dc.contributor.authorSantiago, Pablo-
dc.contributor.authorRechenmacher, Ciliana-
dc.contributor.authorAlegretti, Ana Paula-
dc.contributor.authorRodrigues, Karla-
dc.contributor.authorMagalhães, Mariana Rodrigues de-
dc.contributor.authorDaudt, Liane Esteves-
dc.date.accessioned2022-06-28T12:18:04Z-
dc.date.available2022-06-28T12:18:04Z-
dc.date.issued2021-
dc.identifier.urihttp://higia.imip.org.br/handle/123456789/769-
dc.description.abstractOur group recently showed that the (ASNase) formulation available in Bra-zil from 2017 to 2018 when used at the same dose and frequency as theformulation provided previously did not reach the activity considered ther-apeutic. Based on these, our goal was to assess the impact of these facts onthe prognosis of children with ALL at different oncology centers. A multi-centre retrospective observational study followed by a prospective follow-up. Patients aged>1 and<18 years in first-line treatment followed up at 10referral centres, between 2014 and 2018 who received the formulationLeuginaseâwere identified (Group B). For each patient, the centre regis-tered 2 patients who received ASNase in the presentation of Aginasaâexclusively (Group A). Data collection was registered using (Redcapâ). Atotal of 419 patients were included; 282 in Group A and 137 in B. GroupA had a 3-year OS and EFS of 91 8% and 84 8% respectively, while GroupB had a 3-year OS of 83 8% (P=0 003) and EFS of 76 1% (P=0 008).There was an impact on 3-year OS and EFS of children who received a for-mulation. This result highlights the importance of evaluating ASNase andmonitoring its activity.pt_BR
dc.language.isoenpt_BR
dc.subjectAsparaginasept_BR
dc.subjectLeucemia-linfoma linfoblástico de células precursoraspt_BR
dc.subjectCriançapt_BR
dc.titleInfluence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled studypt_BR
dc.higia.programArtigos científicos colaboradores IMIPpt_BR
dc.higia.tipoArtigo Científicopt_BR
dc.higia.pages6 p.pt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Lins MM-2021.pdf232 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.